# NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

> **NCT04136184** · PHASE3 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 168 (actual)

## Conditions studied

- Hereditary Transthyretin-Mediated Amyloid Polyneuropathy

## Interventions

- **DRUG:** Inotersen
- **DRUG:** Eplontersen

## Key facts

- **NCT ID:** NCT04136184
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-11
- **Primary completion:** 2023-04-11
- **Final completion:** 2023-07-12
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2024-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04136184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04136184, "NEURO-TTRansform: A Study to Evaluate the Efficacy and Safety of Eplontersen (Formerly Known as ION-682884, IONIS-TTR-LRx and AKCEA-TTR-LRx) in Participants With Hereditary Transthyretin-Mediated Amyloid Polyneuropathy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04136184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*